Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct 1:4:95-105.
doi: 10.4137/CMO.S4088.

Pazopanib for the treatment of patients with advanced renal cell carcinoma

Joshua M Lang  1 , Michael R Harrison
Affiliations

Pazopanib for the treatment of patients with advanced renal cell carcinoma

Joshua M Lang et al. Clin Med Insights Oncol. .

Abstract

Dramatic advances in the care of patients with advanced renal cell carcinoma have occurred over the last ten years, including insights into the molecular pathogenesis of this disease, that have now been translated into paradigm-changing therapeutic strategies. Elucidating the importance of signaling cascades related to angiogenesis is notable among these achievements. Pazopanib is a novel small molecule tyrosine kinase inhibitor that targets VEGFR-1, -2, and -3; PDGFR-α, PDGFR-β; and c-kit tyrosine kinases. This agent exhibits a distinct pharmacokinetic profile as well as toxicity profile compared to other agents in the class of VEGF signaling pathway inhibitors. This review will discuss the scientific rationale for the development of pazopanib, as well as preclinical and clinical trials that led to approval of pazopanib for patients with advanced renal cell carcinoma. The most recent information, including data from 2010 national meeting of the American Society of Clinical Oncology, and the design of ongoing Phase III trials, will be discussed. Finally, an algorithm utilizing Level I evidence for the treatment of patients with this disease will be proposed.

Keywords: GW786034; VEGF; VEGFR TKI; pazopanib; renal cell carcinoma; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Evidence-based treatment algorithm for treatment-naïve metastatic renal cell carcinoma (category 1). Note: *Temsirolimus is FDA approved for the first line treatment of poor risk or non clear cell histology metastatic renal cell carcinoma (category 1).
Figure 2.
Figure 2.
Evidence-based treatment algorithm for cytokine refractory metastatic renal cell carcinoma (category 1).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. - PubMed
    1. Linehan WM WM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003 Dec;170(6 Pt 1):2163–72. - PubMed
    1. Kim WY, Kaelin WG. Role of VHL Gene Mutation in Human Cancer. J Clin Oncol. 2004;22(24):4991–5004. - PubMed
    1. Linehan WM, Zbar B, Bates BE, Zelefsky MJ, Yang JC. Cancer of the Kidney and Ureter. In: deVita VT HS, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001. pp. 1362–96.
    1. Cohen HT, McGovern FJ. Renal-Cell Carcinoma. N Engl J Med. 2005;353(23):2477–90. - PubMed

LinkOut - more resources